Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.
Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.
Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.
Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.
Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.
Arbutus Biopharma has announced promising results for its HBV treatment candidate, AB-729, which achieved a mean HBsAg decline of -1.87 log10 IU/mL after 44 weeks. In a clinical trial, 75% of subjects receiving AB-729 at 60 mg every 4 weeks had HBsAg levels below 100 IU/mL. Additionally, AB-729 demonstrated a favorable safety profile and showed potential for increased immune responses. The company is set to initiate Phase 2a trials later this year. The efficacy and safety data support AB-729 as a leading candidate in chronic hepatitis B treatment.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced acceptance of five abstracts for the International Liver Congress 2021, focusing on chronic hepatitis B virus (HBV) treatments. Key presentations include a late-breaker on the GalNAc-siRNA AB-729, demonstrating HBsAg suppression, and the preclinical profile of the HBV capsid inhibitor AB-836. A conference call is scheduled for June 28, 2021, to discuss these findings. Hepatitis B continues to pose significant health challenges globally, affecting over 250 million people.
Arbutus Biopharma Corporation (Nasdaq: ABUS), focused on chronic hepatitis B virus (HBV) and coronavirus therapies, announced participation in two virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 2, 2021, featuring a fireside chat at 9:00 am ET. Presenters include CEO William Collier and other executives. The second is the JMP Securities Life Sciences Conference on June 17, 2021, at 11:00 am ET, also featuring a fireside chat. Links to webcasts are available on their website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q1 2021 results, showcasing advancements in its HBV pipeline, particularly with AB-729 and AB-836. AB-729 has shown significant declines in hepatitis B surface antigen levels with promising safety profiles. The company commenced a Phase 2 clinical trial for a combination regimen involving AB-729 and other treatments for chronic HBV. Financially, Arbutus ended Q1 with $132 million in cash but recorded a net loss of $19.6 million. The firm anticipates significant data releases and trial advancements in the coming quarters.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its first quarter 2021 financial results and corporate update scheduled for May 5, 2021. Key details include the release of the financial results at 7:30 a.m. ET followed by a conference call/webcast at 8:45 a.m. ET. The domestic dial-in number for the call is (866) 393-1607, and international callers can reach (914) 495-8556 with conference ID 4445858. Arbutus focuses on developing treatments for chronic hepatitis B and coronaviruses.
Arbutus Biopharma (NASDAQ: ABUS), in collaboration with X-Chem and Proteros, has announced a new agreement to discover oral inhibitors targeting the SARS-CoV-2 nsp5 main protease. This partnership aims to speed up the development of treatments for COVID-19 and future coronaviruses. The collaboration leverages Arbutus's antiviral expertise, X-Chem's DNA-encoded library technology, and Proteros' structural biology capabilities. The financial terms of the agreement remain undisclosed, and the goal is to identify unique antiviral therapies that can lead to oral treatments for coronavirus-related diseases.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has received regulatory approval to start a Phase 1a/1b clinical trial for AB-836, its oral capsid inhibitor targeting chronic hepatitis B virus (HBV) infection. The trial initiation is a significant milestone toward potential combinations with AB-729. Pre-clinical studies suggest that AB-836 may offer improved efficacy and safety compared to earlier capsid inhibitors. This candidate has demonstrated activity against resistant HBV variants, highlighting its potential in a large patient population suffering from chronic HBV, estimated at over 250 million globally.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported robust clinical progress for its lead compound, AB-729, an RNAi agent targeting chronic hepatitis B (HBV). The latest data show significant declines in hepatitis B surface antigen (HBsAg) levels, with favorable safety profiles. Upcoming clinical trials include Phase 2 combinations of AB-729 with core inhibitors. Financially, the company ended 2020 with $123.3 million in cash, a reduction in net loss to $75.9 million, and reduced expenses, projecting a cash runway through Q3 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation focuses on the company's efforts to develop a cure for chronic hepatitis B virus (HBV) infections and therapies for coronaviruses, including COVID-19. Interested parties can access the webcast on Arbutus' website starting at 7:00 am (EST) on March 9, with an archived replay available afterward.
Assembly Biosciences and Arbutus Biopharma have initiated a Phase 2 clinical trial to evaluate the combination of Assembly's vebicorvir (VBR) and Arbutus’ AB-729 with standard NrtI therapy for chronic hepatitis B Virus (HBV) infection. The trial aims to enroll around 60 patients and assess the safety and antiviral activity of the treatments over 48 weeks. Both companies believe this multi-drug approach is essential for achieving a durable functional cure for HBV, addressing the significant unmet need in HBV therapies.
FAQ
What is the current stock price of Arbutus Biopharma Corporation (ABUS)?
What is the market cap of Arbutus Biopharma Corporation (ABUS)?
What is Arbutus Biopharma's primary focus?
What is imdusiran (AB-729)?
What are the key recent achievements of Arbutus Biopharma?
What is the status of Arbutus' financial condition?
What technologies does Arbutus leverage for its treatments?
What are the current projects Arbutus Biopharma is working on?
Has Arbutus formed any strategic partnerships?
What is the significance of Arbutus' patent litigation?
How successful have Arbutus' clinical trials been?
Where can more information about Arbutus Biopharma be found?
